← Leaderboards
Sean Edward Lawler
Brown University
$3,677,386
Attributed
$7,013,492
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.7M · FY2019–25$2M$1.5M$1M$500K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,013,492 · 4
By mechanism
R01$5,749,548 · 2
T32$853,283 · 1
R21$410,661 · 1
Top collaborators
- Charles H Cook6 shared
- Bradley Lether Pentelute6 shared
- Elena Oancea4 shared
- Anita L Zimmerman1 shared
Others in their field
Other Emerging Leaders on “Clinical Trials”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Bambra Strokes · Ppd Development Lp$526,656,217
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Leonard Freedman · Leidos Biomedical Research, Inc.$245,363,765
- Beth Baseler · Leidos Biomedical Research, Inc.$207,964,226
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$177,411,785
Research focus
Clinical TrialsMouse ModelBrain NeoplasmsGlioblastomaStandard Of CareTumorOperative Surgical ProceduresIn VivoResistanceTemozolomidePreventMalignant - DescriptorImproved OutcomeTherapeutically EffectiveImmunocompetentImmunotherapyTumor GrowthPatient-Focused OutcomesMolecularMalignant Neoplasm Of BrainDesignMalignant NeoplasmsResponseCancer Therapy
Grant awards (18)
Defining the role of cytomegalovirus in glioblastoma therapies$653,127
R01 · FY2025 · CA · contact PI
Interdisciplinary training in pharmacological sciences$213,180
T32 · FY2025 · GM
Defining the role of cytomegalovirus in glioblastoma therapies$620,471
R01 · FY2024 · CA · contact PI
Interdisciplinary training in pharmacological sciences$219,744
T32 · FY2024 · GM
Preclinical assessment of efficacy and tumor microenvironment alterations by PPRX-1701 in glioblastoma$181,142
R21 · FY2024 · CA · contact PI
Defining the role of cytomegalovirus in glioblastoma therapies$84,875
R01 · FY2024 · CA · contact PI
Defining the role of cytomegalovirus in glioblastoma therapies$648,427
R01 · FY2023 · CA · contact PI
Fluorinated macrocyclic peptides as BBB penetrating agent for improved GBM treatment$511,916
R01 · FY2023 · CA · contact PI
Preclinical assessment of efficacy and tumor microenvironment alterations by PPRX-1701 in glioblastoma$229,519
R21 · FY2023 · CA · contact PI
Interdisciplinary training in pharmacological sciences$212,214
T32 · FY2023 · GM
Defining the role of cytomegalovirus in glioblastoma therapies$89,342
R01 · FY2023 · CA · contact PI
Defining the role of cytomegalovirus in glioblastoma therapies$688,910
R01 · FY2022 · CA · contact PI
Fluorinated macrocyclic peptides as BBB penetrating agent for improved GBM treatment$516,442
R01 · FY2022 · CA · contact PI
Interdisciplinary training in pharmacological sciences$208,145
T32 · FY2022 · GM
Fluorinated macrocyclic peptides as BBB penetrating agent for improved GBM treatment$441,111
R01 · FY2021 · CA · contact PI
Fluorinated macrocyclic peptides as BBB penetrating agent for improved GBM treatment$276,125
R01 · FY2021 · CA · contact PI
Fluorinated macrocyclic peptides as BBB penetrating agent for improved GBM treatment$599,526
R01 · FY2020 · CA · contact PI
Fluorinated macrocyclic peptides as BBB penetrating agent for improved GBM treatment$619,276
R01 · FY2019 · CA · contact PI